198 related articles for article (PubMed ID: 24119901)
21. Preclinical pharmacological evaluation of letrozole as a novel treatment for gliomas.
Dave N; Chow LM; Gudelsky GA; LaSance K; Qi X; Desai PB
Mol Cancer Ther; 2015 Apr; 14(4):857-64. PubMed ID: 25695958
[TBL] [Abstract][Full Text] [Related]
22. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
Wong C; Wang X; Smith D; Reddy K; Chen S
Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627
[TBL] [Abstract][Full Text] [Related]
23. Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.
Wang J; Gildea JJ; Yue W
Oncogene; 2013 Oct; 32(44):5233-40. PubMed ID: 23178495
[TBL] [Abstract][Full Text] [Related]
24. Effect of letrozole on estradiol production and P450 aromatase messenger RNA expression of cultured luteinized granulosa cells from women with and without endometriosis.
Lu X; Wu Y; Gao XH; Wang YW; Wang L; Sun XX
Fertil Steril; 2012 Jul; 98(1):131-5. PubMed ID: 22578533
[TBL] [Abstract][Full Text] [Related]
25. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
[TBL] [Abstract][Full Text] [Related]
26. Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Khatri R; Shah P; Guha R; Rassool FV; Tomkinson AE; Brodie A; Jaiswal AK
Mol Cancer Ther; 2015 Jul; 14(7):1728-37. PubMed ID: 25976679
[TBL] [Abstract][Full Text] [Related]
27. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
[TBL] [Abstract][Full Text] [Related]
28. Functional investigation on aromatase in endometrial hyperplasia in polycystic ovary syndrome cases.
Zhao PL; Zhang QF; Yan LY; Huang S; Chen Y; Qiao J
Asian Pac J Cancer Prev; 2014; 15(20):8975-9. PubMed ID: 25374239
[TBL] [Abstract][Full Text] [Related]
29. Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.
Schech AJ; Nemieboka BE; Brodie AH
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):195-202. PubMed ID: 22659283
[TBL] [Abstract][Full Text] [Related]
30. The effects of Nobiletin, Hesperetin, and Letrozole in a combination on the activity and expression of aromatase in breast cancer cells.
Rahideh ST; Keramatipour M; Nourbakhsh M; Koohdani F; Hoseini M; Shidfar F
Cell Mol Biol (Noisy-le-grand); 2017 Feb; 63(2):9-13. PubMed ID: 28364779
[TBL] [Abstract][Full Text] [Related]
31. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Sonne-Hansen K; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
[TBL] [Abstract][Full Text] [Related]
32. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
33. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
34. Synergistic activity of letrozole and sorafenib on breast cancer cells.
Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
[TBL] [Abstract][Full Text] [Related]
35. Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.
Dabydeen SA; Kang K; Díaz-Cruz ES; Alamri A; Axelrod ML; Bouker KB; Al-Kharboosh R; Clarke R; Hennighausen L; Furth PA
Carcinogenesis; 2015 Jan; 36(1):122-32. PubMed ID: 25421723
[TBL] [Abstract][Full Text] [Related]
36. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J
BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652
[TBL] [Abstract][Full Text] [Related]
37. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
[TBL] [Abstract][Full Text] [Related]
38. Letrozole sensitizes breast cancer cells to ionizing radiation.
Azria D; Larbouret C; Cunat S; Ozsahin M; Gourgou S; Martineau P; Evans DB; Romieu G; Pujol P; Pèlegrin A
Breast Cancer Res; 2005; 7(1):R156-63. PubMed ID: 15642164
[TBL] [Abstract][Full Text] [Related]
39. Stopping treatment can reverse acquired resistance to letrozole.
Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM
Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495
[TBL] [Abstract][Full Text] [Related]
40. Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Banerjee S; A'Hern R; Detre S; Littlewood-Evans AJ; Evans DB; Dowsett M; Martin LA
Clin Cancer Res; 2010 Aug; 16(16):4178-87. PubMed ID: 20682704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
